APO Research
Talk to an analyst

APO RESEARCH · REPORT

Coronary Interventional Devices

Coronary artery disease (CAD) is a progressive, focal-to-diffuse atherosclerotic disorder of the epicardial coronary arteries that limits myocardial perfusion by fixed stenosis, dynamic vasomotion, or acute thrombosis after plaque disruption. Atherogenesis begins with endothelial dysfunction and intimal lipid accumulation, evolves to fibroatheroma with variable fibrous-cap thickness, and frequently calcifies over time through both intimal and medial pathways. Thin-cap fibroatheroma predisposes to rupture and thrombosis, whereas heavily calcified, fibrotic lesions resist dilation and require plaque-modification to regain compliance. Clinically, CAD spans stable ischemia, supply–demand mismatch, and acute coronary syndromes (ACS: STEMI and NSTEMI/unstable angina). Contemporary management combines optimal medical therapy with revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), selected according to anatomy, ischemic burden, ventricular function, and comorbidity. PCI is the dominant revascularization strategy for most focal epicardial lesions because it restores luminal caliber with low access morbidity, provided devices can cross, prepare, and durably treat the target segment without provoking edge injury, malapposition, or flow-limiting dissection.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Coronary artery disease (CAD) is a progressive, focal-to-diffuse atherosclerotic disorder of the epicardial coronary arteries that limits myocardial perfusion by fixed stenosis, dynamic vasomotion, or acute thrombosis after plaque disruption. Atherogenesis begins with endothelial dysfunction and intimal lipid accumulation, evolves to fibroatheroma with variable fibrous-cap thickness, and frequently calcifies over time through both intimal and medial pathways. Thin-cap fibroatheroma predisposes to rupture and thrombosis, whereas heavily calcified, fibrotic lesions resist dilation and require plaque-modification to regain compliance. Clinically, CAD spans stable ischemia, supply–demand mismatch, and acute coronary syndromes (ACS: STEMI and NSTEMI/unstable angina). Contemporary management combines optimal medical therapy with revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), selected according to anatomy, ischemic burden, ventricular function, and comorbidity. PCI is the dominant revascularization strategy for most focal epicardial lesions because it restores luminal caliber with low access morbidity, provided devices can cross, prepare, and durably treat the target segment without provoking edge injury, malapposition, or flow-limiting dissection.

Coronary interventional devices are the dedicated toolkit for PCI, engineered to cross, prepare, and definitively treat atherosclerotic stenoses and occlusions in the epicardial coronary arteries while minimizing trauma to the vessel wall and preserving perfusion. In market and clinical terms, these products form the coronary subset of vascular interventional devices and are distinct from equipment for peripheral, neurovascular, aortic, structural heart, or electrophysiology procedures. Their design reflects coronary-specific constraints—arterial diameters most commonly in the 2.0–5.0 mm range, tortuosity and calcification that impair deliverability, and the need for precise deployment within moving, endothelialized conduits subject to cyclic strain.

Clinical workflow anchors the taxonomy. Radial or femoral access is established with sheaths and guiding catheters sized to provide backup support while preserving coronary flow. A 0.014-inch guidewire—selected for tip load, coating, and support profile—crosses the lesion, often aided by single- or dual-lumen microcatheters for torque transmission, wire exchange, or collateral navigation. Lesion preparation uses balloons and, when calcium or fibrotic burden prevents adequate expansion, targeted plaque-modification systems. Definitive therapy centers on stent implantation for de-novo lesions, complemented by drug-coated balloons where “leave-nothing-behind” strategies or in-stent restenosis (ISR) call for antiproliferative delivery without additional metal. Intravascular imaging and physiology devices are used throughout to size, optimize, and adjudicate necessity, thereby improving procedural efficiency and long-term patency.

Balloon catheters are the workhorse interface between wire and lesion. Conventional compliant balloons conform at low inflation pressures and are used for pre-dilation in softer lesions; non-compliant balloons resist dog-boning and transmit force for post-dilation and precise stent expansion. Specialty platforms—scoring or cutting balloons with embedded elements to create controlled intimal fractures, perfusion balloons for prolonged inflation while maintaining downstream flow, and super-compliant balloons for delicate anatomies—extend this spectrum. Drug-coated balloons (DCB) transpose the concept of local drug delivery to a transient implant: a balloon surface formulation and excipient system transfers antiproliferative agents—historically paclitaxel, increasingly sirolimus-family drugs—into the vessel wall during a single sustained inflation, favoring indications such as ISR and small-vessel disease where permanent scaffolds are undesirable.

Stents remain the dominant definitive therapy for most de-novo epicardial lesions. Contemporary drug-eluting stents (DES) integrate three tightly coupled subsystems: an ultra-thin metallic scaffold, a polymer matrix, and an anti-restenotic drug. Cobalt-chromium or platinum-chromium platforms balance radial strength with deliverability and low recoil; strut thickness has trended downward to reduce flow disturbance while maintaining fatigue resistance. Polymer systems range from durable fluorinated or co-polymer films to bioresorbable coatings that elute sirolimus-class drugs over weeks to months and then vanish, aiming to mitigate chronic polymer-related inflammation. Engineering priorities are consistent across portfolios: crossing profile, trackability in tortuous segments, expansion uniformity at rated and high-pressure inflations, radiopacity for precise positioning, and fatigue life under pulsatile, bending, and torsional loads. Covered stents are reserved for perforations, aneurysmal segments, or vein-graft pathology; bioresorbable scaffolds are niche due to historical strut-thickness and late-event concerns but continue to evolve in materials and architecture.

When calcium is the limiting lesion substrate, plaque-modification devices create compliance safely before definitive therapy. Rotational atherectomy ablates superficial calcium using a diamond-coated burr spinning at high speed over a dedicated wire, preferentially modifying inelastic plaque while sparing elastic tissue; orbital atherectomy achieves a similar effect with an eccentrically mounted crown that widens its orbit as speed increases. Excimer laser catheters photoablate fibrocalcific and thrombotic components in calcified, ISR, or under-expanded stent scenarios. Intravascular lithotripsy (IVL) uses acoustic pressure waves generated within a semi-compliant balloon to fracture deep circumferential calcium, enabling lower-pressure balloon expansion and symmetric stent deployment. The common endpoint across these technologies is not debulking for its own sake but restoration of vessel compliance to achieve full-apposed, round stent expansion or, in DCB strategies, adequate drug transfer.

Adjunctive technologies refine decision-making and optimize outcomes. Intravascular ultrasound (IVUS) provides deep wall penetration to assess external elastic lamina, plaque distribution, and minimal stent area; optical coherence tomography (OCT) offers micrometer-scale axial resolution to visualize strut expansion, malapposition, tissue protrusion, and edge dissections. Hybrid modalities combine compositional assessment with morphology. On the physiologic side, pressure-sensing guidewires quantify translesional gradients under hyperemia as fractional flow reserve (FFR) or in resting state as instantaneous wave-free ratio (iFR); microcirculatory indices such as CFR and IMR contextualize epicardial versus microvascular limitations. These devices are not “services” but regulated medical devices sold as capital consoles and single-use sterile disposables, increasingly integral to routine practice because they link anatomic optimization to clinical endpoints.

Because CAD anatomy and biology directly determine device choice and spend, applications are best mapped to lesion archetypes. De-novo lesions dominate volumes and are typically treated with a PTCA-balloon-plus-DES sequence, with imaging and high-pressure post-dilation to secure minimal stent area and proper expansion indices. ISR and small-vessel disease are the natural domain of DCB, prioritizing antiproliferative delivery without additional metal while reserving repeat stent implantation for suboptimal preparation or recoil. Complex lesions—severe concentric or nodular calcification, bifurcations requiring two-stent strategies, chronic total occlusions, left-main disease, and saphenous vein graft pathology—consume higher-value toolsets: plaque-modification systems to achieve compliance, dedicated bifurcation balloons and microcatheters for wire re-crossing, guide-extension catheters for deliverability, and embolic protection in degenerated grafts.

Materials and engineering parameters underpin deliverability, safety, and durability. Guiding catheters are typically multi-layer extrusions with inner PTFE liners for low friction, metallic braid or coil reinforcement for torque and backup support, and outer Pebax or polyurethane jackets with hydrophilic or fluoropolymer surface treatments to reduce insertion forces. Common French sizes are 5–7 F, with internal diameters roughly 0.056–0.081 inch depending on curve and brand; shapes (e.g., Judkins, Amplatz/EBU, Ikari) tune ostial engagement and support. Guide extensions add 20–40 cm of coaxial reach and are constructed with thin-wall PTFE liners plus braid for push and kink resistance. Microcatheters use Pebax-based shafts with stainless-steel or nitinol braid/coil blends, PTFE or HDPE inner liners, and distal marker bands; outer hydrophilic coatings improve trackability in tortuous or collateral channels. Dual-lumen designs enable wire-through-wire re-entry in bifurcation and CTO work. Typical outer diameters run 2.2–2.9 F with pushability/trackability traded against crossing profile.

PTCA balloons combine a high-modulus balloon material with a reinforced shaft. Non-compliant balloons predominantly use biaxially oriented PET or high-modulus polyamides (PA12/PA11) to achieve tight compliance and high rated burst pressures; compliant or semi-compliant designs may blend Pebax or polyurethane for greater conformability. Typical nominal inflation pressures are 6–12 atm for compliant balloons with rated burst pressures around 12–16 atm; non-compliant balloons commonly reach 16–20 atm rated burst pressure, with specialty high-pressure variants exceeding that range for post-dilation of under-expanded scaffolds. Crossing profiles for modern coronary balloons often fall near 0.016–0.026 inch depending on diameter and shaft design. Shafts are multi-layer extrusions with inner PTFE liners, stainless-steel hypotube proximal segments for push, and distal polymer shafts with braid to balance torque and flexibility; hydrophilic or fluoropolymer outer coatings reduce friction. Specialty scoring/cutting balloons incorporate nitinol or stainless scoring elements or micro-blades bonded to the balloon; perfusion balloons include micro-channels to maintain distal flow during prolonged inflations; super-compliant balloons use elastomeric blends for low-pressure conformal sealing in delicate anatomies. Drug-coated balloons add a drug–excipient coating engineered for rapid transfer with minimal particulate shedding; paclitaxel coatings rely on high lipophilicity for quick uptake, while sirolimus-family coatings often use micro-reservoirs or crystalline carriers to enhance tissue penetration and dwell.

Drug-eluting stents use metallic scaffolds laser-cut from thin-wall tubing, electropolished and often surface-conditioned to reduce micro-notches. Cobalt-chromium alloys such as L-605/MP35N and platinum-chromium variants provide high yield strength with thin struts, good radiopacity, and corrosion resistance; legacy 316L stainless steel persists in some platforms. Modern strut thickness commonly ranges from roughly 60 to 90 micrometers to balance hemodynamics and fatigue life. Balloon-expandable delivery balloons are typically non-compliant PET with precise compliance charts; nominal expansion pressures are around 9–12 atm with rated burst pressures up to roughly 18–20 atm to ensure full apposition. The polymer matrix is either durable (e.g., fluorinated copolymers and acrylics) or bioresorbable (e.g., PLGA/PCL families), applied in thin coats on the order of a few to low-two-digit micrometers, and loaded with sirolimus-class drugs such as everolimus, zotarolimus, or biolimus with total drug mass scaled to stent surface area. Elution kinetics are tuned to deliver a substantial fraction of dose over weeks to a few months while minimizing late polymer presence and particulate generation during crimp and expansion. Covered stents for perforation control commonly use expanded PTFE or polyurethane membranes bonded to metallic scaffolds. Bioresorbable scaffolds historically used poly-L-lactic acid with struts about 150 micrometers and resorption spanning two to three years; newer designs explore magnesium alloys that resorb more rapidly while preserving early radial support.

Guidewires couple core metallurgy and tip architecture to lesion strategy. Stainless-steel cores provide excellent torque and tip shaping, while nitinol cores confer kink resistance and elastic recovery; hybrid cores and DFT (drawn-filled-tube) constructions add radiopacity and signal fidelity for pressure/temperature sensors. Tip loads from sub-gram to low-two-digit grams cover glide-biased to penetration-biased behavior; hydrophilic polyurethane or polyimide coatings reduce friction, whereas hydrophobic PTFE segments balance tactile feedback. Radiopaque platinum coils or shaping ribbons at the distal tip improve visualization and maintain atraumatic profiles. CTO wires layer tapered cores, high-penetration tips, and polymer jackets to navigate micro-channels or re-enter the true lumen.

Compatibility standards and interfaces ensure system coherence. French sizes for access hardware gate internal diameters and tool combinations; 0.014-inch wire platforms define lumen size through balloons, microcatheters, and stent systems; radiopaque marker bands, proximal hub color codes, and standardized luer connections simplify workflow and reduce error. Sterilization is predominantly ethylene oxide for polymer-rich disposables; implants undergo mechanical validation for hoop strength, recoil, foreshortening, longitudinal integrity, and fatigue under simulated coronary bending and torsional spectra over hundreds of millions of cycles equivalent to multi-year physiologic strain.

Innovation vectors are coherent across the category. Stents continue to pursue thinner struts without mechanical compromise, bioresorbable or ultra-inert polymers that minimize late events, and drug kinetics tuned to lesion biology. DCBs are migrating from paclitaxel to sirolimus-based systems with advanced excipients targeting deeper, sustained arterial wall uptake while maintaining low particulate emission. Calcium-modifying tools are broadening indications as data mature, elevating routine use in concentric and eccentric heavy calcification to avoid under-expanded scaffolds—a root cause of restenosis and thrombosis. Imaging and physiology are moving toward integrated, wire-free or monorail-compatible workflows, automated stent optimization metrics, and co-registration of angiography with intravascular maps to shorten procedures and standardize quality.

From a market structure standpoint, the treatment spine dominates value: stents as the anchor implant, PTCA balloons as universal enablers, DCB as the principal leave-nothing-behind therapy, and plaque-modification as a selective but rising high-value adjunct in calcified disease. Access and guidance components, guidewires and microcatheters, thrombus management and graft protection, imaging, and physiology form the complementary ecosystem that converts anatomical and biological heterogeneity into reproducible, durable revascularization. The category’s defining attribute is not any single device but the engineered interoperability—guide, wire, catheter, balloon, implant, energy delivery, imaging, and measurement—optimized for coronary anatomy and for the clinical objective of achieving complete revascularization with the least implanted burden and the highest long-term patency.

Selected research

Industry Growth & Trends

Global Coronary Interventional Devices Industry Growth and Trends Forecast to 2032

21 December 2025126 pages

Choose your research edition.

Industry ResearchCoronary Interventional Devices Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Coronary Interventional Devices Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Coronary Interventional Devices Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Coronary Interventional Devices Market Outlook and Growth Opportunities 2026210 pages · $4,250 USDMarket Analysis & ForecastGlobal Coronary Interventional Devices Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

Coronary artery disease (CAD) is a progressive, focal-to-diffuse atherosclerotic disorder of the epicardial coronary arteries that limits myocardial perfusion by fixed stenosis, dynamic vasomotion, or acute thrombosis after plaque disruption. Atherogenesis begins with endothelial dysfunction and intimal lipid accumulation, evolves to fibroatheroma with variable fibrous-cap thickness, and frequently calcifies over time through both intimal and medial pathways. Thin-cap fibroatheroma predisposes to rupture and thrombosis, whereas heavily calcified, fibrotic lesions resist dilation and require plaque-modification to regain compliance. Clinically, CAD spans stable ischemia, supply–demand mismatch, and acute coronary syndromes (ACS: STEMI and NSTEMI/unstable angina). Contemporary management combines optimal medical therapy with revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), selected according to anatomy, ischemic burden, ventricular function, and comorbidity. PCI is the dominant revascularization strategy for most focal epicardial lesions because it restores luminal caliber with low access morbidity, provided devices can cross, prepare, and durably treat the target segment without provoking edge injury, malapposition, or flow-limiting dissection.

Coronary interventional devices are the dedicated toolkit for PCI, engineered to cross, prepare, and definitively treat atherosclerotic stenoses and occlusions in the epicardial coronary arteries while minimizing trauma to the vessel wall and preserving perfusion. In market and clinical terms, these products form the coronary subset of vascular interventional devices and are distinct from equipment for peripheral, neurovascular, aortic, structural heart, or electrophysiology procedures. Their design reflects coronary-specific constraints—arterial diameters most commonly in the 2.0–5.0 mm range, tortuosity and calcification that impair deliverability, and the need for precise deployment within moving, endothelialized conduits subject to cyclic strain.

Clinical workflow anchors the taxonomy. Radial or femoral access is established with sheaths and guiding catheters sized to provide backup support while preserving coronary flow. A 0.014-inch guidewire—selected for tip load, coating, and support profile—crosses the lesion, often aided by single- or dual-lumen microcatheters for torque transmission, wire exchange, or collateral navigation. Lesion preparation uses balloons and, when calcium or fibrotic burden prevents adequate expansion, targeted plaque-modification systems. Definitive therapy centers on stent implantation for de-novo lesions, complemented by drug-coated balloons where “leave-nothing-behind” strategies or in-stent restenosis (ISR) call for antiproliferative delivery without additional metal. Intravascular imaging and physiology devices are used throughout to size, optimize, and adjudicate necessity, thereby improving procedural efficiency and long-term patency.

Read the full market overview

Balloon catheters are the workhorse interface between wire and lesion. Conventional compliant balloons conform at low inflation pressures and are used for pre-dilation in softer lesions; non-compliant balloons resist dog-boning and transmit force for post-dilation and precise stent expansion. Specialty platforms—scoring or cutting balloons with embedded elements to create controlled intimal fractures, perfusion balloons for prolonged inflation while maintaining downstream flow, and super-compliant balloons for delicate anatomies—extend this spectrum. Drug-coated balloons (DCB) transpose the concept of local drug delivery to a transient implant: a balloon surface formulation and excipient system transfers antiproliferative agents—historically paclitaxel, increasingly sirolimus-family drugs—into the vessel wall during a single sustained inflation, favoring indications such as ISR and small-vessel disease where permanent scaffolds are undesirable.

Stents remain the dominant definitive therapy for most de-novo epicardial lesions. Contemporary drug-eluting stents (DES) integrate three tightly coupled subsystems: an ultra-thin metallic scaffold, a polymer matrix, and an anti-restenotic drug. Cobalt-chromium or platinum-chromium platforms balance radial strength with deliverability and low recoil; strut thickness has trended downward to reduce flow disturbance while maintaining fatigue resistance. Polymer systems range from durable fluorinated or co-polymer films to bioresorbable coatings that elute sirolimus-class drugs over weeks to months and then vanish, aiming to mitigate chronic polymer-related inflammation. Engineering priorities are consistent across portfolios: crossing profile, trackability in tortuous segments, expansion uniformity at rated and high-pressure inflations, radiopacity for precise positioning, and fatigue life under pulsatile, bending, and torsional loads. Covered stents are reserved for perforations, aneurysmal segments, or vein-graft pathology; bioresorbable scaffolds are niche due to historical strut-thickness and late-event concerns but continue to evolve in materials and architecture.

When calcium is the limiting lesion substrate, plaque-modification devices create compliance safely before definitive therapy. Rotational atherectomy ablates superficial calcium using a diamond-coated burr spinning at high speed over a dedicated wire, preferentially modifying inelastic plaque while sparing elastic tissue; orbital atherectomy achieves a similar effect with an eccentrically mounted crown that widens its orbit as speed increases. Excimer laser catheters photoablate fibrocalcific and thrombotic components in calcified, ISR, or under-expanded stent scenarios. Intravascular lithotripsy (IVL) uses acoustic pressure waves generated within a semi-compliant balloon to fracture deep circumferential calcium, enabling lower-pressure balloon expansion and symmetric stent deployment. The common endpoint across these technologies is not debulking for its own sake but restoration of vessel compliance to achieve full-apposed, round stent expansion or, in DCB strategies, adequate drug transfer.

Adjunctive technologies refine decision-making and optimize outcomes. Intravascular ultrasound (IVUS) provides deep wall penetration to assess external elastic lamina, plaque distribution, and minimal stent area; optical coherence tomography (OCT) offers micrometer-scale axial resolution to visualize strut expansion, malapposition, tissue protrusion, and edge dissections. Hybrid modalities combine compositional assessment with morphology. On the physiologic side, pressure-sensing guidewires quantify translesional gradients under hyperemia as fractional flow reserve (FFR) or in resting state as instantaneous wave-free ratio (iFR); microcirculatory indices such as CFR and IMR contextualize epicardial versus microvascular limitations. These devices are not “services” but regulated medical devices sold as capital consoles and single-use sterile disposables, increasingly integral to routine practice because they link anatomic optimization to clinical endpoints.

Because CAD anatomy and biology directly determine device choice and spend, applications are best mapped to lesion archetypes. De-novo lesions dominate volumes and are typically treated with a PTCA-balloon-plus-DES sequence, with imaging and high-pressure post-dilation to secure minimal stent area and proper expansion indices. ISR and small-vessel disease are the natural domain of DCB, prioritizing antiproliferative delivery without additional metal while reserving repeat stent implantation for suboptimal preparation or recoil. Complex lesions—severe concentric or nodular calcification, bifurcations requiring two-stent strategies, chronic total occlusions, left-main disease, and saphenous vein graft pathology—consume higher-value toolsets: plaque-modification systems to achieve compliance, dedicated bifurcation balloons and microcatheters for wire re-crossing, guide-extension catheters for deliverability, and embolic protection in degenerated grafts.

Materials and engineering parameters underpin deliverability, safety, and durability. Guiding catheters are typically multi-layer extrusions with inner PTFE liners for low friction, metallic braid or coil reinforcement for torque and backup support, and outer Pebax or polyurethane jackets with hydrophilic or fluoropolymer surface treatments to reduce insertion forces. Common French sizes are 5–7 F, with internal diameters roughly 0.056–0.081 inch depending on curve and brand; shapes (e.g., Judkins, Amplatz/EBU, Ikari) tune ostial engagement and support. Guide extensions add 20–40 cm of coaxial reach and are constructed with thin-wall PTFE liners plus braid for push and kink resistance. Microcatheters use Pebax-based shafts with stainless-steel or nitinol braid/coil blends, PTFE or HDPE inner liners, and distal marker bands; outer hydrophilic coatings improve trackability in tortuous or collateral channels. Dual-lumen designs enable wire-through-wire re-entry in bifurcation and CTO work. Typical outer diameters run 2.2–2.9 F with pushability/trackability traded against crossing profile.

PTCA balloons combine a high-modulus balloon material with a reinforced shaft. Non-compliant balloons predominantly use biaxially oriented PET or high-modulus polyamides (PA12/PA11) to achieve tight compliance and high rated burst pressures; compliant or semi-compliant designs may blend Pebax or polyurethane for greater conformability. Typical nominal inflation pressures are 6–12 atm for compliant balloons with rated burst pressures around 12–16 atm; non-compliant balloons commonly reach 16–20 atm rated burst pressure, with specialty high-pressure variants exceeding that range for post-dilation of under-expanded scaffolds. Crossing profiles for modern coronary balloons often fall near 0.016–0.026 inch depending on diameter and shaft design. Shafts are multi-layer extrusions with inner PTFE liners, stainless-steel hypotube proximal segments for push, and distal polymer shafts with braid to balance torque and flexibility; hydrophilic or fluoropolymer outer coatings reduce friction. Specialty scoring/cutting balloons incorporate nitinol or stainless scoring elements or micro-blades bonded to the balloon; perfusion balloons include micro-channels to maintain distal flow during prolonged inflations; super-compliant balloons use elastomeric blends for low-pressure conformal sealing in delicate anatomies. Drug-coated balloons add a drug–excipient coating engineered for rapid transfer with minimal particulate shedding; paclitaxel coatings rely on high lipophilicity for quick uptake, while sirolimus-family coatings often use micro-reservoirs or crystalline carriers to enhance tissue penetration and dwell.

Drug-eluting stents use metallic scaffolds laser-cut from thin-wall tubing, electropolished and often surface-conditioned to reduce micro-notches. Cobalt-chromium alloys such as L-605/MP35N and platinum-chromium variants provide high yield strength with thin struts, good radiopacity, and corrosion resistance; legacy 316L stainless steel persists in some platforms. Modern strut thickness commonly ranges from roughly 60 to 90 micrometers to balance hemodynamics and fatigue life. Balloon-expandable delivery balloons are typically non-compliant PET with precise compliance charts; nominal expansion pressures are around 9–12 atm with rated burst pressures up to roughly 18–20 atm to ensure full apposition. The polymer matrix is either durable (e.g., fluorinated copolymers and acrylics) or bioresorbable (e.g., PLGA/PCL families), applied in thin coats on the order of a few to low-two-digit micrometers, and loaded with sirolimus-class drugs such as everolimus, zotarolimus, or biolimus with total drug mass scaled to stent surface area. Elution kinetics are tuned to deliver a substantial fraction of dose over weeks to a few months while minimizing late polymer presence and particulate generation during crimp and expansion. Covered stents for perforation control commonly use expanded PTFE or polyurethane membranes bonded to metallic scaffolds. Bioresorbable scaffolds historically used poly-L-lactic acid with struts about 150 micrometers and resorption spanning two to three years; newer designs explore magnesium alloys that resorb more rapidly while preserving early radial support.

Guidewires couple core metallurgy and tip architecture to lesion strategy. Stainless-steel cores provide excellent torque and tip shaping, while nitinol cores confer kink resistance and elastic recovery; hybrid cores and DFT (drawn-filled-tube) constructions add radiopacity and signal fidelity for pressure/temperature sensors. Tip loads from sub-gram to low-two-digit grams cover glide-biased to penetration-biased behavior; hydrophilic polyurethane or polyimide coatings reduce friction, whereas hydrophobic PTFE segments balance tactile feedback. Radiopaque platinum coils or shaping ribbons at the distal tip improve visualization and maintain atraumatic profiles. CTO wires layer tapered cores, high-penetration tips, and polymer jackets to navigate micro-channels or re-enter the true lumen.

Compatibility standards and interfaces ensure system coherence. French sizes for access hardware gate internal diameters and tool combinations; 0.014-inch wire platforms define lumen size through balloons, microcatheters, and stent systems; radiopaque marker bands, proximal hub color codes, and standardized luer connections simplify workflow and reduce error. Sterilization is predominantly ethylene oxide for polymer-rich disposables; implants undergo mechanical validation for hoop strength, recoil, foreshortening, longitudinal integrity, and fatigue under simulated coronary bending and torsional spectra over hundreds of millions of cycles equivalent to multi-year physiologic strain.

Innovation vectors are coherent across the category. Stents continue to pursue thinner struts without mechanical compromise, bioresorbable or ultra-inert polymers that minimize late events, and drug kinetics tuned to lesion biology. DCBs are migrating from paclitaxel to sirolimus-based systems with advanced excipients targeting deeper, sustained arterial wall uptake while maintaining low particulate emission. Calcium-modifying tools are broadening indications as data mature, elevating routine use in concentric and eccentric heavy calcification to avoid under-expanded scaffolds—a root cause of restenosis and thrombosis. Imaging and physiology are moving toward integrated, wire-free or monorail-compatible workflows, automated stent optimization metrics, and co-registration of angiography with intravascular maps to shorten procedures and standardize quality.

From a market structure standpoint, the treatment spine dominates value: stents as the anchor implant, PTCA balloons as universal enablers, DCB as the principal leave-nothing-behind therapy, and plaque-modification as a selective but rising high-value adjunct in calcified disease. Access and guidance components, guidewires and microcatheters, thrombus management and graft protection, imaging, and physiology form the complementary ecosystem that converts anatomical and biological heterogeneity into reproducible, durable revascularization. The category’s defining attribute is not any single device but the engineered interoperability—guide, wire, catheter, balloon, implant, energy delivery, imaging, and measurement—optimized for coronary anatomy and for the clinical objective of achieving complete revascularization with the least implanted burden and the highest long-term patency.

The global Coronary Interventional Devices market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Coronary Interventional Devices is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Coronary Interventional Devices is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

The Asia Pacific market for Coronary Interventional Devices is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Coronary Interventional Devices include Abbott, LifeTech, MicroPort, Sino Medical, Medtronic, Lepu Medical, Boston Scientific, B. Braun and Terumo Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Coronary Interventional Devices market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Coronary Interventional Devices market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Coronary Interventional Devices market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Coronary Interventional Devices.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Coronary Interventional Devices market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Coronary Interventional Devices Market by Company

Abbott

LifeTech

MicroPort

Sino Medical

Medtronic

Lepu Medical

Boston Scientific

B. Braun

Terumo Corporation

Nipro

Kaneka

Asahi Intecc

BrosMed Medical

Demax Medical

Yinyi Biotech

OrbusNeich Medical

DK Medical

Cordis

Weigao Group

JW Medical

Biotronik

Teleflex

Coronary Interventional Devices Segment by Type

Stents (DES, BMS, BRS)

PTCA Balloons

DCB

Other

Coronary Interventional Devices Segment by Application

De-novo

ISR/SVD

Complex

Coronary Interventional Devices Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Coronary Interventional Devices market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Coronary Interventional Devices and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Coronary Interventional Devices.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Coronary Interventional Devices manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Coronary Interventional Devices in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Stents (DES, BMS, BRS) Table 2. Major Company of PTCA Balloons Table 3. Major Company of DCB Table 4. Major Company of Other Table 5. Global Coronary Interventional Devices Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Coronary Interventional Devices Sales by Type (2021-2026) & (k units) Table 7. Global Coronary Interventional Devices Sales Market Share in Volume by Type (2021-2026) Table 8. Global Coronary Interventional Devices Sales by Type (2021-2026) & (US$ Million) Table 9. Global Coronary Interventional Devices Sales Market Share in Value by Type (2021-2026) Table 10. Global Coronary Interventional Devices Price by Type (2021-2026) & (USD/unit) Table 11. Global Coronary Interventional Devices Sales by Type (2027-2032) & (k units) Table 12. Global Coronary Interventional Devices Sales Market Share in Volume by Type (2027-2032) Table 13. Global Coronary Interventional Devices Sales by Type (2027-2032) & (US$ Million) Table 14. Global Coronary Interventional Devices Sales Market Share in Value by Type (2027-2032) Table 15. Global Coronary Interventional Devices Price by Type (2027-2032) & (USD/unit) Table 16. North America Coronary Interventional Devices Sales by Type (2021-2026) & (k units) Table 17. North America Coronary Interventional Devices Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Coronary Interventional Devices Sales by Type (2021-2026) & (k units) Table 19. Europe Coronary Interventional Devices Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Coronary Interventional Devices Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Coronary Interventional Devices Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Coronary Interventional Devices Sales by Type (2021-2026) & (k units) Table 23. Latin America Coronary Interventional Devices Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Coronary Interventional Devices Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Coronary Interventional Devices Sales by Type (2021-2026) & (US$ Million) Table 26. Coronary Interventional Devices Industry Trends Table 27. Coronary Interventional Devices Industry Drivers Table 28. Coronary Interventional Devices Industry Opportunities and Challenges Table 29. Coronary Interventional Devices Industry Restraints Table 30. Global Coronary Interventional Devices Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Coronary Interventional Devices Revenue Market Share by Company (2021-2026) Table 32. Global Coronary Interventional Devices Sales by Company (2021-2026) & (k units) Table 33. Global Coronary Interventional Devices Sales Share by Company (2021-2026) Table 34. Global Coronary Interventional Devices Market Price by Company (2021-2026) & (USD/unit) Table 35. Global Coronary Interventional Devices Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Coronary Interventional Devices Major Company Production Sites and Headquarters Table 37. Global Coronary Interventional Devices Company, Product Type & Application Table 38. Global Coronary Interventional Devices Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Coronary Interventional Devices by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Coronary Interventional Devices Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Coronary Interventional Devices Sales by Region (2021-2026) & (k units) Table 43. Global Coronary Interventional Devices Sales Market Share in Volume by Region (2021-2026) Table 44. Global Coronary Interventional Devices Sales by Region (2021-2026) & (US$ Million) Table 45. Global Coronary Interventional Devices Sales Market Share in Value by Region (2021-2026) Table 46. Global Coronary Interventional Devices Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 47. Global Coronary Interventional Devices Sales by Region (2027-2032) & (k units) Table 48. Global Coronary Interventional Devices Sales Market Share in Volume by Region (2027-2032) Table 49. Global Coronary Interventional Devices Sales by Region (2027-2032) & (US$ Million) Table 50. Global Coronary Interventional Devices Sales Market Share in Value by Region (2027-2032) Table 51. Global Coronary Interventional Devices Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2027-2032) Table 52. Global Coronary Interventional Devices Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Coronary Interventional Devices Sales by Application (2021-2026) & (k units) Table 54. Global Coronary Interventional Devices Sales Market Share in Volume by Application (2021-2026) Table 55. Global Coronary Interventional Devices Sales by Application (2021-2026) & (US$ Million) Table 56. Global Coronary Interventional Devices Sales Market Share in Value by Application (2021-2026) Table 57. Global Coronary Interventional Devices Price by Application (2021-2026) & (USD/unit) Table 58. Global Coronary Interventional Devices Sales by Application (2027-2032) & (k units) Table 59. Global Coronary Interventional Devices Sales Market Share in Volume by Application (2027-2032) Table 60. Global Coronary Interventional Devices Sales by Application (2027-2032) & (US$ Million) Table 61. Global Coronary Interventional Devices Sales Market Share in Value by Application (2027-2032) Table 62. Global Coronary Interventional Devices Price by Application (2027-2032) & (USD/unit) Table 63. North America Coronary Interventional Devices Sales by Application (2021-2026) & (k units) Table 64. North America Coronary Interventional Devices Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Coronary Interventional Devices Sales by Application (2021-2026) & (k units) Table 66. Europe Coronary Interventional Devices Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Coronary Interventional Devices Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Coronary Interventional Devices Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Coronary Interventional Devices Sales by Application (2021-2026) & (k units) Table 70. Latin America Coronary Interventional Devices Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Coronary Interventional Devices Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Coronary Interventional Devices Sales by Application (2021-2026) & (US$ Million) Table 73. Abbott Company Information Table 74. Abbott Business Overview Table 75. Abbott Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Abbott Coronary Interventional Devices Product Portfolio Table 77. Abbott Recent Development Table 78. LifeTech Company Information Table 79. LifeTech Business Overview Table 80. LifeTech Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. LifeTech Coronary Interventional Devices Product Portfolio Table 82. LifeTech Recent Development Table 83. MicroPort Company Information Table 84. MicroPort Business Overview Table 85. MicroPort Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. MicroPort Coronary Interventional Devices Product Portfolio Table 87. MicroPort Recent Development Table 88. Sino Medical Company Information Table 89. Sino Medical Business Overview Table 90. Sino Medical Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Sino Medical Coronary Interventional Devices Product Portfolio Table 92. Sino Medical Recent Development Table 93. Medtronic Company Information Table 94. Medtronic Business Overview Table 95. Medtronic Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Medtronic Coronary Interventional Devices Product Portfolio Table 97. Medtronic Recent Development Table 98. Lepu Medical Company Information Table 99. Lepu Medical Business Overview Table 100. Lepu Medical Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Lepu Medical Coronary Interventional Devices Product Portfolio Table 102. Lepu Medical Recent Development Table 103. Boston Scientific Company Information Table 104. Boston Scientific Business Overview Table 105. Boston Scientific Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Boston Scientific Coronary Interventional Devices Product Portfolio Table 107. Boston Scientific Recent Development Table 108. B. Braun Company Information Table 109. B. Braun Business Overview Table 110. B. Braun Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. B. Braun Coronary Interventional Devices Product Portfolio Table 112. B. Braun Recent Development Table 113. Terumo Corporation Company Information Table 114. Terumo Corporation Business Overview Table 115. Terumo Corporation Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Terumo Corporation Coronary Interventional Devices Product Portfolio Table 117. Terumo Corporation Recent Development Table 118. Nipro Company Information Table 119. Nipro Business Overview Table 120. Nipro Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Nipro Coronary Interventional Devices Product Portfolio Table 122. Nipro Recent Development Table 123. Kaneka Company Information Table 124. Kaneka Business Overview Table 125. Kaneka Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Kaneka Coronary Interventional Devices Product Portfolio Table 127. Kaneka Recent Development Table 128. Asahi Intecc Company Information Table 129. Asahi Intecc Business Overview Table 130. Asahi Intecc Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Asahi Intecc Coronary Interventional Devices Product Portfolio Table 132. Asahi Intecc Recent Development Table 133. BrosMed Medical Company Information Table 134. BrosMed Medical Business Overview Table 135. BrosMed Medical Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. BrosMed Medical Coronary Interventional Devices Product Portfolio Table 137. BrosMed Medical Recent Development Table 138. Demax Medical Company Information Table 139. Demax Medical Business Overview Table 140. Demax Medical Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. Demax Medical Coronary Interventional Devices Product Portfolio Table 142. Demax Medical Recent Development Table 143. Yinyi Biotech Company Information Table 144. Yinyi Biotech Business Overview Table 145. Yinyi Biotech Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. Yinyi Biotech Coronary Interventional Devices Product Portfolio Table 147. Yinyi Biotech Recent Development Table 148. OrbusNeich Medical Company Information Table 149. OrbusNeich Medical Business Overview Table 150. OrbusNeich Medical Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 151. OrbusNeich Medical Coronary Interventional Devices Product Portfolio Table 152. OrbusNeich Medical Recent Development Table 153. DK Medical Company Information Table 154. DK Medical Business Overview Table 155. DK Medical Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 156. DK Medical Coronary Interventional Devices Product Portfolio Table 157. DK Medical Recent Development Table 158. Cordis Company Information Table 159. Cordis Business Overview Table 160. Cordis Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 161. Cordis Coronary Interventional Devices Product Portfolio Table 162. Cordis Recent Development Table 163. Weigao Group Company Information Table 164. Weigao Group Business Overview Table 165. Weigao Group Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 166. Weigao Group Coronary Interventional Devices Product Portfolio Table 167. Weigao Group Recent Development Table 168. JW Medical Company Information Table 169. JW Medical Business Overview Table 170. JW Medical Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 171. JW Medical Coronary Interventional Devices Product Portfolio Table 172. JW Medical Recent Development Table 173. Biotronik Company Information Table 174. Biotronik Business Overview Table 175. Biotronik Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 176. Biotronik Coronary Interventional Devices Product Portfolio Table 177. Biotronik Recent Development Table 178. Teleflex Company Information Table 179. Teleflex Business Overview Table 180. Teleflex Coronary Interventional Devices Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 181. Teleflex Coronary Interventional Devices Product Portfolio Table 182. Teleflex Recent Development Table 183. North America Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 184. North America Coronary Interventional Devices Sales by Country (2021-2026) & (k units) Table 185. North America Coronary Interventional Devices Sales Market Share by Country (2021-2026) Table 186. North America Coronary Interventional Devices Sales Forecast by Country (2027-2032) & (k units) Table 187. North America Coronary Interventional Devices Sales Market Share Forecast by Country (2027-2032) Table 188. North America Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. North America Coronary Interventional Devices Market Size by Country (2021-2026) & (US$ Million) Table 190. North America Coronary Interventional Devices Market Share by Country (2021-2026) Table 191. North America Coronary Interventional Devices Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. North America Coronary Interventional Devices Market Share Forecast by Country (2027-2032) Table 193. Europe Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 194. Europe Coronary Interventional Devices Sales by Country (2021-2026) & (k units) Table 195. Europe Coronary Interventional Devices Sales Market Share by Country (2021-2026) Table 196. Europe Coronary Interventional Devices Sales Forecast by Country (2027-2032) & (k units) Table 197. Europe Coronary Interventional Devices Sales Market Share Forecast by Country (2027-2032) Table 198. Europe Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 199. Europe Coronary Interventional Devices Market Size by Country (2021-2026) & (US$ Million) Table 200. Europe Coronary Interventional Devices Market Share by Country (2021-2026) Table 201. Europe Coronary Interventional Devices Market Size Forecast by Country (2027-2032) & (US$ Million) Table 202. Europe Coronary Interventional Devices Market Share Forecast by Country (2027-2032) Table 203. Asia-Pacific Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 204. Asia-Pacific Coronary Interventional Devices Sales by Country (2021-2026) & (k units) Table 205. Asia-Pacific Coronary Interventional Devices Sales Market Share by Country (2021-2026) Table 206. Asia-Pacific Coronary Interventional Devices Sales Forecast by Country (2027-2032) & (k units) Table 207. Asia-Pacific Coronary Interventional Devices Sales Market Share Forecast by Country (2027-2032) Table 208. Asia-Pacific Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 209. Asia-Pacific Coronary Interventional Devices Market Size by Country (2021-2026) & (US$ Million) Table 210. Asia-Pacific Coronary Interventional Devices Market Share by Country (2021-2026) Table 211. Asia-Pacific Coronary Interventional Devices Market Size Forecast by Country (2027-2032) & (US$ Million) Table 212. Asia-Pacific Coronary Interventional Devices Market Share Forecast by Country (2027-2032) Table 213. Latin America Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 214. Latin America Coronary Interventional Devices Sales by Country (2021-2026) & (k units) Table 215. Latin America Coronary Interventional Devices Sales Market Share by Country (2021-2026) Table 216. Latin America Coronary Interventional Devices Sales Forecast by Country (2027-2032) & (k units) Table 217. Latin America Coronary Interventional Devices Sales Market Share Forecast by Country (2027-2032) Table 218. Latin America Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 219. Latin America Coronary Interventional Devices Market Size by Country (2021-2026) & (US$ Million) Table 220. Latin America Coronary Interventional Devices Market Share by Country (2021-2026) Table 221. Latin America Coronary Interventional Devices Market Size Forecast by Country (2027-2032) & (US$ Million) Table 222. Latin America Coronary Interventional Devices Market Share Forecast by Country (2027-2032) Table 223. Middle East and Africa Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 224. Middle East and Africa Coronary Interventional Devices Sales by Country (2021-2026) & (k units) Table 225. Middle East and Africa Coronary Interventional Devices Sales Market Share by Country (2021-2026) Table 226. Middle East and Africa Coronary Interventional Devices Sales Forecast by Country (2027-2032) & (k units) Table 227. Middle East and Africa Coronary Interventional Devices Sales Market Share Forecast by Country (2027-2032) Table 228. Middle East and Africa Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 229. Middle East and Africa Coronary Interventional Devices Market Size by Country (2021-2026) & (US$ Million) Table 230. Middle East and Africa Coronary Interventional Devices Market Share by Country (2021-2026) Table 231. Middle East and Africa Coronary Interventional Devices Market Size Forecast by Country (2027-2032) & (US$ Million) Table 232. Middle East and Africa Coronary Interventional Devices Market Share Forecast by Country (2027-2032) Table 233. Key Raw Materials Table 234. Raw Materials Key Suppliers Table 235. Coronary Interventional Devices Distributors List Table 236. Coronary Interventional Devices Customers List Table 237. Research Programs/Design for This Report Table 238. Authors List of This Report Table 239. Secondary Sources Table 240. Primary Sources List of Figures Figure 1. Coronary Interventional Devices Image Figure 2. Global Coronary Interventional Devices Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Coronary Interventional Devices Market Size (2021-2032) & (US$ Million) Figure 4. Global Coronary Interventional Devices Sales (2021-2032) & (k units) Figure 5. Stents (DES, BMS, BRS) Image Figure 6. Global Stents (DES, BMS, BRS) Sales YoY Growth (2021-2032) & (k units) Figure 7. PTCA Balloons Image Figure 8. Global PTCA Balloons Sales YoY Growth (2021-2032) & (k units) Figure 9. DCB Image Figure 10. Global DCB Sales YoY Growth (2021-2032) & (k units) Figure 11. Other Image Figure 12. Global Other Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Coronary Interventional Devices Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Coronary Interventional Devices Market Share by Type 2025 VS 2032 Figure 15. North America Coronary Interventional Devices Sales Market Share in Volume by Type in 2025 Figure 16. North America Coronary Interventional Devices Sales Market Share in Value by Type in 2025 Figure 17. Europe Coronary Interventional Devices Sales Market Share in Volume by Type in 2025 Figure 18. Europe Coronary Interventional Devices Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Coronary Interventional Devices Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Coronary Interventional Devices Sales Market Share in Value by Type in 2025 Figure 21. Latin America Coronary Interventional Devices Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Coronary Interventional Devices Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Coronary Interventional Devices Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Coronary Interventional Devices Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Coronary Interventional Devices Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. De-novo Image Figure 28. Global De-novo Sales YoY Growth (2021-2032) & (k units) Figure 29. ISR/SVD Image Figure 30. Global ISR/SVD Sales YoY Growth (2021-2032) & (k units) Figure 31. Complex Image Figure 32. Global Complex Sales YoY Growth (2021-2032) & (k units) Figure 33. Global Coronary Interventional Devices Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Coronary Interventional Devices Market Share by Application 2025 VS 2032 Figure 35. North America Coronary Interventional Devices Sales Market Share in Volume by Application in 2025 Figure 36. North America Coronary Interventional Devices Sales Market Share in Value by Application in 2025 Figure 37. Europe Coronary Interventional Devices Sales Market Share in Volume by Application in 2025 Figure 38. Europe Coronary Interventional Devices Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Coronary Interventional Devices Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Coronary Interventional Devices Sales Market Share in Value by Application in 2025 Figure 41. Latin America Coronary Interventional Devices Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Coronary Interventional Devices Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Coronary Interventional Devices Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Coronary Interventional Devices Sales Market Share in Value by Application in 2025 Figure 45. North America Coronary Interventional Devices Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America Coronary Interventional Devices Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Coronary Interventional Devices Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Coronary Interventional Devices Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Coronary Interventional Devices Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe Coronary Interventional Devices Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Coronary Interventional Devices Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Coronary Interventional Devices Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Coronary Interventional Devices Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific Coronary Interventional Devices Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Coronary Interventional Devices Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Coronary Interventional Devices Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Coronary Interventional Devices Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America Coronary Interventional Devices Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Coronary Interventional Devices Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Coronary Interventional Devices Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Coronary Interventional Devices Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Middle East and Africa Coronary Interventional Devices Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Coronary Interventional Devices Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Coronary Interventional Devices Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Coronary Interventional Devices Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Coronary Interventional Devices Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Stents (DES, BMS, BRS)
  • PTCA Balloons
  • DCB
  • Other
Applications
  • De-novo
  • ISR/SVD
  • Complex
Companies covered
  • Abbott
  • LifeTech
  • MicroPort
  • Sino Medical
  • Medtronic
  • Lepu Medical
  • Boston Scientific
  • B. Braun
  • Terumo Corporation
  • Nipro
  • Kaneka
  • Asahi Intecc
  • BrosMed Medical
  • Demax Medical
  • Yinyi Biotech
  • OrbusNeich Medical
  • DK Medical
  • Cordis
  • Weigao Group
  • JW Medical
  • Biotronik
  • Teleflex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Coronary Interventional Devices Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Coronary Interventional Devices Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Coronary Interventional Devices Market by Type
  6. 1.3.1 Stents (DES, BMS, BRS)
  7. 1.3.2 PTCA Balloons
  8. 1.3.3 DCB
  9. 1.3.4 Other
  10. 1.4 Global Coronary Interventional Devices Market Size by Type
  11. 1.4.1 Global Coronary Interventional Devices Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Coronary Interventional Devices Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Coronary Interventional Devices Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Coronary Interventional Devices Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Coronary Interventional Devices Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Coronary Interventional Devices Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Coronary Interventional Devices Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Coronary Interventional Devices Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Coronary Interventional Devices Industry Trends
  2. 2.2 Coronary Interventional Devices Industry Drivers
  3. 2.3 Coronary Interventional Devices Industry Opportunities and Challenges
  4. 2.4 Coronary Interventional Devices Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Coronary Interventional Devices Revenue (2021-2026)
  2. 3.2 Global Top Players by Coronary Interventional Devices Sales (2021-2026)
  3. 3.3 Global Top Players by Coronary Interventional Devices Price (2021-2026)
  4. 3.4 Global Coronary Interventional Devices Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Coronary Interventional Devices Major Company Production Sites & Headquarters
  6. 3.6 Global Coronary Interventional Devices Company, Product Type & Application
  7. 3.7 Global Coronary Interventional Devices Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Coronary Interventional Devices Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Coronary Interventional Devices Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Coronary Interventional Devices Tier 1, Tier 2, and Tier 3
4 Coronary Interventional Devices Regional Status and Outlook
  1. 4.1 Global Coronary Interventional Devices Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Coronary Interventional Devices Historic Market Size by Region
  3. 4.2.1 Global Coronary Interventional Devices Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Coronary Interventional Devices Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Coronary Interventional Devices Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Coronary Interventional Devices Forecasted Market Size by Region
  7. 4.3.1 Global Coronary Interventional Devices Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Coronary Interventional Devices Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Coronary Interventional Devices Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Coronary Interventional Devices by Application
  1. 5.1 Coronary Interventional Devices Market by Application
  2. 5.1.1 De-novo
  3. 5.1.2 ISR/SVD
  4. 5.1.3 Complex
  5. 5.2 Global Coronary Interventional Devices Market Size by Application
  6. 5.2.1 Global Coronary Interventional Devices Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Coronary Interventional Devices Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Coronary Interventional Devices Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Coronary Interventional Devices Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Coronary Interventional Devices Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Coronary Interventional Devices Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Coronary Interventional Devices Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Coronary Interventional Devices Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Abbott
  2. 6.1.1 Abbott Company Information
  3. 6.1.2 Abbott Business Overview
  4. 6.1.3 Abbott Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Abbott Coronary Interventional Devices Product Portfolio
  6. 6.1.5 Abbott Recent Developments
  7. 6.2 LifeTech
  8. 6.2.1 LifeTech Company Information
  9. 6.2.2 LifeTech Business Overview
  10. 6.2.3 LifeTech Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 LifeTech Coronary Interventional Devices Product Portfolio
  12. 6.2.5 LifeTech Recent Developments
  13. 6.3 MicroPort
  14. 6.3.1 MicroPort Company Information
  15. 6.3.2 MicroPort Business Overview
  16. 6.3.3 MicroPort Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 MicroPort Coronary Interventional Devices Product Portfolio
  18. 6.3.5 MicroPort Recent Developments
  19. 6.4 Sino Medical
  20. 6.4.1 Sino Medical Company Information
  21. 6.4.2 Sino Medical Business Overview
  22. 6.4.3 Sino Medical Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Sino Medical Coronary Interventional Devices Product Portfolio
  24. 6.4.5 Sino Medical Recent Developments
  25. 6.5 Medtronic
  26. 6.5.1 Medtronic Company Information
  27. 6.5.2 Medtronic Business Overview
  28. 6.5.3 Medtronic Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Medtronic Coronary Interventional Devices Product Portfolio
  30. 6.5.5 Medtronic Recent Developments
  31. 6.6 Lepu Medical
  32. 6.6.1 Lepu Medical Company Information
  33. 6.6.2 Lepu Medical Business Overview
  34. 6.6.3 Lepu Medical Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Lepu Medical Coronary Interventional Devices Product Portfolio
  36. 6.6.5 Lepu Medical Recent Developments
  37. 6.7 Boston Scientific
  38. 6.7.1 Boston Scientific Company Information
  39. 6.7.2 Boston Scientific Business Overview
  40. 6.7.3 Boston Scientific Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Boston Scientific Coronary Interventional Devices Product Portfolio
  42. 6.7.5 Boston Scientific Recent Developments
  43. 6.8 B. Braun
  44. 6.8.1 B. Braun Company Information
  45. 6.8.2 B. Braun Business Overview
  46. 6.8.3 B. Braun Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 B. Braun Coronary Interventional Devices Product Portfolio
  48. 6.8.5 B. Braun Recent Developments
  49. 6.9 Terumo Corporation
  50. 6.9.1 Terumo Corporation Company Information
  51. 6.9.2 Terumo Corporation Business Overview
  52. 6.9.3 Terumo Corporation Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Terumo Corporation Coronary Interventional Devices Product Portfolio
  54. 6.9.5 Terumo Corporation Recent Developments
  55. 6.10 Nipro
  56. 6.10.1 Nipro Company Information
  57. 6.10.2 Nipro Business Overview
  58. 6.10.3 Nipro Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Nipro Coronary Interventional Devices Product Portfolio
  60. 6.10.5 Nipro Recent Developments
  61. 6.11 Kaneka
  62. 6.11.1 Kaneka Company Information
  63. 6.11.2 Kaneka Business Overview
  64. 6.11.3 Kaneka Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Kaneka Coronary Interventional Devices Product Portfolio
  66. 6.11.5 Kaneka Recent Developments
  67. 6.12 Asahi Intecc
  68. 6.12.1 Asahi Intecc Company Information
  69. 6.12.2 Asahi Intecc Business Overview
  70. 6.12.3 Asahi Intecc Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Asahi Intecc Coronary Interventional Devices Product Portfolio
  72. 6.12.5 Asahi Intecc Recent Developments
  73. 6.13 BrosMed Medical
  74. 6.13.1 BrosMed Medical Company Information
  75. 6.13.2 BrosMed Medical Business Overview
  76. 6.13.3 BrosMed Medical Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 BrosMed Medical Coronary Interventional Devices Product Portfolio
  78. 6.13.5 BrosMed Medical Recent Developments
  79. 6.14 Demax Medical
  80. 6.14.1 Demax Medical Company Information
  81. 6.14.2 Demax Medical Business Overview
  82. 6.14.3 Demax Medical Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Demax Medical Coronary Interventional Devices Product Portfolio
  84. 6.14.5 Demax Medical Recent Developments
  85. 6.15 Yinyi Biotech
  86. 6.15.1 Yinyi Biotech Company Information
  87. 6.15.2 Yinyi Biotech Business Overview
  88. 6.15.3 Yinyi Biotech Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Yinyi Biotech Coronary Interventional Devices Product Portfolio
  90. 6.15.5 Yinyi Biotech Recent Developments
  91. 6.16 OrbusNeich Medical
  92. 6.16.1 OrbusNeich Medical Company Information
  93. 6.16.2 OrbusNeich Medical Business Overview
  94. 6.16.3 OrbusNeich Medical Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 OrbusNeich Medical Coronary Interventional Devices Product Portfolio
  96. 6.16.5 OrbusNeich Medical Recent Developments
  97. 6.17 DK Medical
  98. 6.17.1 DK Medical Company Information
  99. 6.17.2 DK Medical Business Overview
  100. 6.17.3 DK Medical Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 DK Medical Coronary Interventional Devices Product Portfolio
  102. 6.17.5 DK Medical Recent Developments
  103. 6.18 Cordis
  104. 6.18.1 Cordis Company Information
  105. 6.18.2 Cordis Business Overview
  106. 6.18.3 Cordis Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Cordis Coronary Interventional Devices Product Portfolio
  108. 6.18.5 Cordis Recent Developments
  109. 6.19 Weigao Group
  110. 6.19.1 Weigao Group Company Information
  111. 6.19.2 Weigao Group Business Overview
  112. 6.19.3 Weigao Group Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Weigao Group Coronary Interventional Devices Product Portfolio
  114. 6.19.5 Weigao Group Recent Developments
  115. 6.20 JW Medical
  116. 6.20.1 JW Medical Company Information
  117. 6.20.2 JW Medical Business Overview
  118. 6.20.3 JW Medical Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 JW Medical Coronary Interventional Devices Product Portfolio
  120. 6.20.5 JW Medical Recent Developments
  121. 6.21 Biotronik
  122. 6.21.1 Biotronik Company Information
  123. 6.21.2 Biotronik Business Overview
  124. 6.21.3 Biotronik Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Biotronik Coronary Interventional Devices Product Portfolio
  126. 6.21.5 Biotronik Recent Developments
  127. 6.22 Teleflex
  128. 6.22.1 Teleflex Company Information
  129. 6.22.2 Teleflex Business Overview
  130. 6.22.3 Teleflex Coronary Interventional Devices Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Teleflex Coronary Interventional Devices Product Portfolio
  132. 6.22.5 Teleflex Recent Developments
7 North America by Country
  1. 7.1 North America Coronary Interventional Devices Sales by Country
  2. 7.1.1 North America Coronary Interventional Devices Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Coronary Interventional Devices Sales by Country (2021-2026)
  4. 7.1.3 North America Coronary Interventional Devices Sales Forecast by Country (2027-2032)
  5. 7.2 North America Coronary Interventional Devices Market Size by Country
  6. 7.2.1 North America Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Coronary Interventional Devices Market Size by Country (2021-2026)
  8. 7.2.3 North America Coronary Interventional Devices Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Coronary Interventional Devices Sales by Country
  2. 8.1.1 Europe Coronary Interventional Devices Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Coronary Interventional Devices Sales by Country (2021-2026)
  4. 8.1.3 Europe Coronary Interventional Devices Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Coronary Interventional Devices Market Size by Country
  6. 8.2.1 Europe Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Coronary Interventional Devices Market Size by Country (2021-2026)
  8. 8.2.3 Europe Coronary Interventional Devices Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Coronary Interventional Devices Sales by Country
  2. 9.1.1 Asia-Pacific Coronary Interventional Devices Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Coronary Interventional Devices Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Coronary Interventional Devices Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Coronary Interventional Devices Market Size by Country
  6. 9.2.1 Asia-Pacific Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Coronary Interventional Devices Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Coronary Interventional Devices Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Coronary Interventional Devices Sales by Country
  2. 10.1.1 South America Coronary Interventional Devices Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Coronary Interventional Devices Sales by Country (2021-2026)
  4. 10.1.3 South America Coronary Interventional Devices Sales Forecast by Country (2027-2032)
  5. 10.2 South America Coronary Interventional Devices Market Size by Country
  6. 10.2.1 South America Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Coronary Interventional Devices Market Size by Country (2021-2026)
  8. 10.2.3 South America Coronary Interventional Devices Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Coronary Interventional Devices Sales by Country
  2. 11.1.1 Middle East and Africa Coronary Interventional Devices Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Coronary Interventional Devices Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Coronary Interventional Devices Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Coronary Interventional Devices Market Size by Country
  6. 11.2.1 Middle East and Africa Coronary Interventional Devices Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Coronary Interventional Devices Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Coronary Interventional Devices Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Coronary Interventional Devices Value Chain Analysis
  2. 12.1.1 Coronary Interventional Devices Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Coronary Interventional Devices Production Mode & Process
  7. 12.2 Coronary Interventional Devices Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Coronary Interventional Devices Distributors
  10. 12.2.3 Coronary Interventional Devices Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst